Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1][2]. Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were overstated, and the company downplayed the severity of issues related to the adulterated devices [2]. - These actions have led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuits [4].

Core Viewpoint - A securities class action lawsuit has been filed against Firefly Aerospace Inc. for allegedly making false and misleading statements regarding its business operations and growth prospects during its IPO and subsequent period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Firefly's common stock during the IPO on August 7, 2025, and those who acquired securities between August 7, 2025, and September 29, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for January 12, 2026 [1][4]. Group 2: Allegations Against Defendants - The complaint alleges that Firefly overstated the demand and growth prospects for its Spacecraft Solutions offerings [3]. - It is claimed that the Alpha rocket program did not meet its expected operational readiness and commercial viability [3]. - As a result of these issues, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3].

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jayud Global Logistics Ltd. (“Jayud” or “the Company”) (NASDAQ: JYD) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Jay ...

Core Points - A class action lawsuit has been filed against Perrigo Company plc and certain officers for alleged violations of federal securities laws during the period from February 27, 2025, to November 4, 2025 [2][4] Group 1: Allegations - The lawsuit claims that Perrigo's management made materially false and misleading statements and failed to disclose significant adverse facts about the company's business and operations [3] - Specific allegations include underinvestment in the infant formula business acquired from Nestlé, the need for substantial capital expenditures beyond stated estimates, and significant manufacturing deficiencies [3] - As a result of these issues, the company's financial results, including earnings and cash flow, were overstated, leading to misleading positive statements about its business prospects [3] Group 2: Legal Process - Investors who suffered losses in Perrigo have until January 16, 2026, to request to be appointed as lead plaintiff in the class action [4] - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5][6]

Core Viewpoint - A class action lawsuit has been filed against Citadel Securities LLC and Virtu Americas LLC on behalf of investors who sold Genius Group Limited securities, alleging manipulative trading practices that artificially deflated the stock price [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks damages for alleged violations of federal securities laws during the Class Period from April 12, 2022, to May 30, 2025 [2]. - The Complaint claims that the Defendants engaged in "spoofing," a trading scheme involving placing and canceling orders without intent to execute, misleading market participants about the true market dynamics of Genius securities [3]. - It is alleged that the Defendants profited by absorbing and reselling customer order flow at favorable prices while building significant short positions in Genius stock [3]. Group 2: Next Steps for Investors - Investors who sold Genius securities have until January 16, 2026, to request to be appointed as lead plaintiff in the case [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6].

SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Stride, Inc. (NYSE: LRN) securities between October 22, 2024 and October 28, 2025, inclusive (the “Class Period”), have until January 12, 2026 to seek appointment as lead plaintiff of the Stride class action lawsuit. Captioned MacMahon v. Stride, Inc., No. 25-cv-02019 (E.D. Va.), the Stride class action lawsuit charges Stride as well as certain of Stride’s top executives wi ...

SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Six Flags Entertainment Corporation f/k/a CopperSteel HoldCo, Inc. (NYSE: FUN) common stock pursuant or traceable to the company’s registration statement and prospectus issued in connection with the July 1, 2024 merger of legacy Six Flags Entertainment Corporation (“Legacy Six Flags”) with Cedar Fair, L.P. (“Cedar Fair”), and their subsidiaries and affiliates (the “Merger”), have until Mon ...

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving uniQure N.V. and its officers or directors [1] - uniQure announced feedback from the FDA indicating that data from Phase I/II studies of its investigational gene therapy AMT-130 may not be sufficient for a Biologics License Application (BLA) submission, leading to a significant drop in stock price [2] Group 1: Company Developments - On November 3, 2025, uniQure received feedback from the FDA during a pre-BLA meeting regarding AMT-130, a gene therapy for Huntington's disease [2] - The FDA's feedback represents a key shift from previous communications, causing uncertainty about the timing of the BLA submission for AMT-130 [2] - Following the announcement, uniQure's stock price fell by $33.40, or 49.34%, closing at $34.29 per share [2] Group 2: Legal Investigations - Pomerantz LLP is actively investigating claims on behalf of investors of uniQure regarding potential securities fraud [1] - The firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3]

Core Viewpoint - Live Oak Bancshares, Inc. is under investigation for potential securities fraud and unlawful business practices following the announcement of material misclassifications in its financial statements [1][2]. Financial Reporting Issues - On November 12, 2025, Live Oak disclosed that it would amend its 2024 Annual Report and Quarterly Reports for the periods ended March 31, 2025, and June 30, 2025, to restate its Consolidated Financial Statements due to errors in cash flow classifications [2]. - The company identified a material weakness in its internal control over financial reporting, indicating that previous financial statements for the affected periods should no longer be relied upon [2]. Market Reaction - Following the announcement of the financial restatement, Live Oak's stock price decreased by $0.80, or 2.49%, closing at $31.29 per share on November 13, 2025 [2].

Core Viewpoint - The Freeport-McMoRan Inc. class action lawsuit alleges violations of the Securities Exchange Act of 1934, focusing on safety issues at the Grasberg mine and the subsequent impact on stock prices [1][4]. Group 1: Class Action Details - Purchasers of Freeport-McMoRan securities between February 15, 2022, and September 24, 2025, can seek lead plaintiff status by January 12, 2026 [1]. - The lawsuit is titled Reed v. Freeport-McMoRan Inc., No. 25-cv-04243 (D. Ariz.) [1]. - The lawsuit claims that Freeport-McMoRan and its executives made misleading statements regarding safety at the Grasberg Block Cave mine [4]. Group 2: Allegations and Incidents - Allegations include inadequate safety measures at the Grasberg mine, which heightened risks for workers and led to regulatory and reputational risks [4]. - On September 9, 2025, Freeport-McMoRan reported a significant incident at the Grasberg mine, resulting in a nearly 6% drop in stock price [5]. - Following a tragic incident on September 24, 2025, where two team members were fatally injured, the stock price fell nearly 17% [6]. - A Bloomberg article on September 25, 2025, highlighted potential strains in Freeport-McMoRan's relationship with the Indonesian government, causing an additional stock price drop of over 6% [7]. Group 3: Company Operations - Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Papua, Indonesia, where the Indonesian government holds a commercial interest [3]. - The company has temporarily suspended mining operations in the Grasberg minerals district since September 8, 2025, to prioritize safety [6].